This segment focuses on the research, development, and clinical trials of novel therapeutics for various anxiety disorders. The primary focus is on PH94B, a rapid-onset neuroactive nasal spray, currently in Phase III development for social anxiety disorder. Research and development activities include formulation development, preclinical studies, and clinical trial management. Technologies employed include nasal delivery systems and neurocircuitry-focused treatments. The segment aims to address the significant unmet needs of patients suffering from social anxiety disorder, adjustment disorder with anxiety, postpartum anxiety, and other anxiety-related conditions. Market positioning is centered on providing fast-acting and effective treatments with potentially fewer side effects compared to existing therapies. Future opportunities include expanding the indications for PH94B and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials to demonstrate safety and efficacy. Partnerships with EverInsight Therapeutics Inc. support development and commercialization in specific regions.

This segment is dedicated to the development of PH10, a rapid-onset neuroactive nasal spray, as a stand-alone treatment for Major Depressive Disorder (MDD). Research and development efforts include Phase 2B clinical trials to evaluate the efficacy and safety of PH10. The segment utilizes nasal delivery technology to provide a fast-acting treatment option for MDD patients. The therapeutic area focuses on addressing the significant burden of MDD, aiming to provide a new treatment option for patients who may not respond to existing therapies. Market positioning involves differentiating PH10 from current antidepressants by offering a potentially faster onset of action. Future opportunities include expanding the clinical program and exploring combination therapies. Regulatory and clinical aspects involve conducting clinical trials and seeking regulatory approval. The segment's success depends on demonstrating the efficacy and safety of PH10 in clinical trials.

This segment focuses on the development of AV-101, an oral N-methyl-D-aspartate receptor antagonist, in combination with probenecid, as a potential treatment for levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. Research and development activities include preclinical studies, clinical trials, and formulation development. The segment leverages the understanding of the NMDAR system to develop targeted therapies for neurological conditions. The therapeutic areas include levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation, addressing significant unmet medical needs. Market positioning involves providing innovative treatment options for complex neurological disorders. Future opportunities include expanding the clinical program and exploring combination therapies. Regulatory and clinical aspects involve conducting clinical trials and seeking regulatory approval. Partnerships and collaborations are essential for advancing the development and commercialization of AV-101.